drugset / Trial / NCT01616654

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654

Phase 2 Completed 304 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Timeline

Start
2012-06-20
Primary completion
2013-07-24
Completion
2014-06-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tazarotene Small molecule 0.1 % Topical
Subject Trifarotene Small molecule 25 unknown Topical
Subject Trifarotene Small molecule 50 unknown Topical
Subject Trifarotene Small molecule 100 unknown Topical

Indications